questionsmedicales.fr
Bactéries
Proteobacteria
Gammaproteobacteria
Vibrionaceae
Vibrio
Vibrio cholerae
Vibrio cholerae : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae : Questions médicales les plus fréquentes",
"headline": "Vibrio cholerae : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vibrio cholerae : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-28",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vibrio",
"url": "https://questionsmedicales.fr/mesh/D014733",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio",
"code": {
"@type": "MedicalCode",
"code": "D014733",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae non-O1",
"alternateName": "Vibrio cholerae non-O1",
"url": "https://questionsmedicales.fr/mesh/D044163",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae non-O1",
"code": {
"@type": "MedicalCode",
"code": "D044163",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.075"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O1",
"alternateName": "Vibrio cholerae O1",
"url": "https://questionsmedicales.fr/mesh/D041241",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O1",
"code": {
"@type": "MedicalCode",
"code": "D041241",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.151"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O139",
"alternateName": "Vibrio cholerae O139",
"url": "https://questionsmedicales.fr/mesh/D041242",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O139",
"code": {
"@type": "MedicalCode",
"code": "D041242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.200"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae",
"alternateName": "Vibrio cholerae",
"code": {
"@type": "MedicalCode",
"code": "D014734",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Firdausi Qadri",
"url": "https://questionsmedicales.fr/author/Firdausi%20Qadri",
"affiliation": {
"@type": "Organization",
"name": "Infectious Diseases Division, icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh."
}
},
{
"@type": "Person",
"name": "Munirul Alam",
"url": "https://questionsmedicales.fr/author/Munirul%20Alam",
"affiliation": {
"@type": "Organization",
"name": "International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh."
}
},
{
"@type": "Person",
"name": "Shanta Dutta",
"url": "https://questionsmedicales.fr/author/Shanta%20Dutta",
"affiliation": {
"@type": "Organization",
"name": "National Institute of Cholera and Enteric Diseases, NICED-JICA Building, 57 Dr. S.C. Banerjee Road, Beliaghata, Kolkata, 700 010, India."
}
},
{
"@type": "Person",
"name": "Shelley M Payne",
"url": "https://questionsmedicales.fr/author/Shelley%20M%20Payne",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA payne@utexas.edu."
}
},
{
"@type": "Person",
"name": "Bibhuti Bhusan Pal",
"url": "https://questionsmedicales.fr/author/Bibhuti%20Bhusan%20Pal",
"affiliation": {
"@type": "Organization",
"name": "Microbiology Division, ICMR-Regional Medical Research Centre, Chandrasekharpur, Bhubaneswar, 751023, Orissa, India. Electronic address: bbpal_rmrc@yahoo.co.in."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.",
"datePublished": "2022-12-20",
"url": "https://questionsmedicales.fr/article/36600424",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-067251"
}
},
{
"@type": "ScholarlyArticle",
"name": "Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.",
"datePublished": "2022-05-23",
"url": "https://questionsmedicales.fr/article/35617986",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2213-2600(22)00088-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial.",
"datePublished": "2024-08-14",
"url": "https://questionsmedicales.fr/article/39161682",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/DDDT.S472651"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of Liposomal Melatonin in sleep EEG in Childhood: A Double Blind Case Control Study.",
"datePublished": "2022-12-29",
"url": "https://questionsmedicales.fr/article/36612875",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20010552"
}
},
{
"@type": "ScholarlyArticle",
"name": "Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.",
"datePublished": "2022-06-20",
"url": "https://questionsmedicales.fr/article/35725922",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41591-022-01861-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Bactéries",
"item": "https://questionsmedicales.fr/mesh/D001419"
},
{
"@type": "ListItem",
"position": 3,
"name": "Proteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020560"
},
{
"@type": "ListItem",
"position": 4,
"name": "Gammaproteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020563"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vibrionaceae",
"item": "https://questionsmedicales.fr/mesh/D014737"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vibrio",
"item": "https://questionsmedicales.fr/mesh/D014733"
},
{
"@type": "ListItem",
"position": 7,
"name": "Vibrio cholerae",
"item": "https://questionsmedicales.fr/mesh/D014734"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vibrio cholerae - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vibrio cholerae",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vibrio cholerae",
"description": "Comment diagnostiquer une infection par Vibrio cholerae ?\nQuels tests sont utilisés pour confirmer le choléra ?\nQuels symptômes indiquent une infection par Vibrio cholerae ?\nQuelle est la période d'incubation du choléra ?\nComment différencier le choléra d'autres diarrhées ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vibrio cholerae",
"description": "Quels sont les principaux symptômes du choléra ?\nComment se manifeste la déshydratation dans le choléra ?\nLe choléra peut-il être asymptomatique ?\nQuels signes indiquent une déshydratation sévère ?\nLes symptômes du choléra apparaissent-ils rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vibrio cholerae",
"description": "Comment prévenir l'infection par Vibrio cholerae ?\nLa vaccination contre le choléra est-elle efficace ?\nQuelles mesures d'hygiène sont recommandées ?\nComment l'eau potable peut-elle prévenir le choléra ?\nLes voyages dans des zones à risque nécessitent-ils des précautions ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vibrio cholerae",
"description": "Quel est le traitement principal du choléra ?\nLes antibiotiques sont-ils nécessaires pour le choléra ?\nComment prévenir la déshydratation dans le choléra ?\nQuels médicaments sont utilisés pour traiter le choléra ?\nLe traitement du choléra est-il efficace ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vibrio cholerae",
"description": "Quelles sont les complications possibles du choléra ?\nLe choléra peut-il entraîner la mort ?\nComment la déshydratation affecte-t-elle le corps ?\nQuelles sont les conséquences à long terme du choléra ?\nLe choléra peut-il causer des épidémies ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vibrio cholerae",
"description": "Quels sont les facteurs de risque du choléra ?\nLes enfants sont-ils plus à risque de choléra ?\nComment la malnutrition influence-t-elle le choléra ?\nLes personnes vivant dans des zones urbaines sont-elles à risque ?\nLes voyageurs peuvent-ils être exposés au choléra ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Double-Blind+Method&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection par Vibrio cholerae ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par culture de selles ou tests PCR pour détecter la bactérie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer le choléra ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de culture des selles et les tests rapides de détection d'antigènes sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une infection par Vibrio cholerae ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent diarrhée aqueuse, vomissements et déshydratation rapide."
}
},
{
"@type": "Question",
"name": "Quelle est la période d'incubation du choléra ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La période d'incubation est généralement de 1 à 5 jours après l'exposition."
}
},
{
"@type": "Question",
"name": "Comment différencier le choléra d'autres diarrhées ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choléra se caractérise par une diarrhée aqueuse profuse et une déshydratation rapide."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux symptômes du choléra ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux symptômes sont diarrhée aqueuse, vomissements, crampes abdominales."
}
},
{
"@type": "Question",
"name": "Comment se manifeste la déshydratation dans le choléra ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "La déshydratation se manifeste par soif intense, sécheresse de la peau et fatigue."
}
},
{
"@type": "Question",
"name": "Le choléra peut-il être asymptomatique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent être porteuses sans présenter de symptômes."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une déshydratation sévère ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent confusion, tachycardie, hypotension et urines très rares."
}
},
{
"@type": "Question",
"name": "Les symptômes du choléra apparaissent-ils rapidement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent apparaître rapidement, souvent dans les 24 heures."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'infection par Vibrio cholerae ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par l'accès à l'eau potable, l'hygiène et la vaccination."
}
},
{
"@type": "Question",
"name": "La vaccination contre le choléra est-elle efficace ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccins peuvent réduire le risque d'infection, surtout en zones à risque."
}
},
{
"@type": "Question",
"name": "Quelles mesures d'hygiène sont recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains fréquemment et consommer des aliments bien cuits sont essentiels."
}
},
{
"@type": "Question",
"name": "Comment l'eau potable peut-elle prévenir le choléra ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'eau potable et propre empêche l'ingestion de Vibrio cholerae, réduisant le risque."
}
},
{
"@type": "Question",
"name": "Les voyages dans des zones à risque nécessitent-ils des précautions ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est conseillé de se faire vacciner et de suivre des mesures d'hygiène strictes."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal du choléra ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la réhydratation orale ou intraveineuse selon la gravité."
}
},
{
"@type": "Question",
"name": "Les antibiotiques sont-ils nécessaires pour le choléra ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques peuvent être utilisés pour réduire la durée de la diarrhée et la gravité."
}
},
{
"@type": "Question",
"name": "Comment prévenir la déshydratation dans le choléra ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réhydratation rapide avec des solutions de réhydratation orale est essentielle."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter le choléra ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques comme la doxycycline ou l'azithromycine sont souvent prescrits."
}
},
{
"@type": "Question",
"name": "Le traitement du choléra est-il efficace ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un traitement rapide et approprié est très efficace pour réduire la mortalité."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du choléra ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent déshydratation sévère, choc hypovolémique et insuffisance rénale."
}
},
{
"@type": "Question",
"name": "Le choléra peut-il entraîner la mort ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement rapide, le choléra peut être mortel en raison de la déshydratation."
}
},
{
"@type": "Question",
"name": "Comment la déshydratation affecte-t-elle le corps ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La déshydratation peut entraîner des déséquilibres électrolytiques et des défaillances organiques."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences à long terme du choléra ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences peuvent inclure des problèmes de santé persistants, comme des troubles digestifs."
}
},
{
"@type": "Question",
"name": "Le choléra peut-il causer des épidémies ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le choléra peut provoquer des épidémies, surtout dans des conditions d'hygiène précaires."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du choléra ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'accès limité à l'eau potable, la malnutrition et l'absence d'hygiène."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus à risque de choléra ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants et les personnes âgées sont plus vulnérables aux complications du choléra."
}
},
{
"@type": "Question",
"name": "Comment la malnutrition influence-t-elle le choléra ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "La malnutrition affaiblit le système immunitaire, augmentant le risque d'infection par choléra."
}
},
{
"@type": "Question",
"name": "Les personnes vivant dans des zones urbaines sont-elles à risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les zones urbaines surpeuplées avec un accès limité à l'eau potable sont à risque."
}
},
{
"@type": "Question",
"name": "Les voyageurs peuvent-ils être exposés au choléra ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyageurs dans des régions endommagées par le choléra doivent prendre des précautions."
}
}
]
}
]
}
Sepsis is a major cause of death among hospitalised patients. Accumulating evidence suggests that immune response during sepsis cascade lies within a spectrum of dysregulated host responses. On the on...
ImmunoSep is a randomised placebo-controlled phase 2 clinical trial with a double-dummy design in which the effect of precision immunotherapy on sepsis phenotypes with MALS and immunoparalysis is stud...
The protocol is approved by the German Federal Institute for Drugs and Medical Devices; the National Ethics Committee of Greece and by the National Organization for Medicines of Greece; the Central Co...
NCT04990232....
Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone p...
In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), a...
Between Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (...
In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in simi...
National Institute of Allergy and Infectious Diseases....
This study aimed to establish the 95% effective dose (ED95) of esketamine in combination with propofol for hysteroscopy and then to evaluate its efficacy and safety profile....
This prospective, double-blind, randomized controlled trial consisted of two cohorts. In cohort 1, 45 women aged 18-65 years undergoing hysteroscopy were randomly assigned to either group E (esketamin...
The ED95 of esketamine was 0.254 mg/kg (95% CI: 0.214-1.004), while that of alfentanil was 9.121 μg/kg (95% CI: 8.479-13.364). The anesthesia success rate was 93.0% in group E and 95.2% in group A (p ...
This study determined the ED 95 dose of esketamine for intravenous general anesthesia during hysteroscopy. Esketamine showed less respiratory and hemodynamic depression, as well as fewer adverse effec...
www.chictr.org.cn, (ChiCTR2300077283); registered November 3, 2023....
Electroencephalography (EEG) is pivotal in the clinical assessment of epilepsy, and sleep is known to improve the diagnostic yield of its recording. Sleep-EEG recording is generally reached by either ...
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease that may advance to fibrosis and lead to mortality; however, no pharmacotherapy is currently available. We tested the hypothesis t...
Rescue of mitochondrial function is a promising neuroprotective strategy for Parkinson's disease (PD). Ursodeoxycholic acid (UDCA) has shown considerable promise as a mitochondrial rescue agent across...
To investigate the safety and tolerability of high-dose UDCA in PD and determine midbrain target engagement....
The UP (UDCA in PD) study was a phase II, randomized, double-blind, placebo-controlled trial of UDCA (30 mg/kg daily, 2:1 randomization UDCA vs. placebo) in 30 participants with PD for 48 weeks. The p...
UDCA was safe and well tolerated, and only mild transient gastrointestinal adverse events were more frequent in the UDCA treatment group. Midbrain...
High-dose UDCA is safe and well tolerated in early PD. Larger trials are needed to further evaluate the disease-modifying effect of UDCA in PD. © 2023 The Authors. Movement Disorders published by Wile...
To determine whether intravenous vitamin C compared with placebo, reduces vasopressor requirements in patients with vasoplegic shock....
Double-blinded, randomised clinical trial (RCT) conducted in two intensive care units in Perth, Australia. Vasopressor requirements at enrolment needed to be >10 μg/min noradrenaline after hypovolaemi...
Of the 71 patients randomised (35 vitamin C, 36 placebo group), the median vasopressor duration was 44 h [95% CI, 37-54 h] and 55 h [95% CI, 33-66 h]) in the vitamin C and placebo groups (p = 0.057). ...
In this RCT of patients with vasoplegic shock of at least moderate severity, the use of IV vitamin C compared with placebo did not significantly reduce the duration of vasopressors....
Prospective registration - trial number ACTRN12617001392358....
Fibrotic hypersensitivity pneumonitis (FHP) is an irreversible lung disease with high morbidity and mortality. We sought to evaluate the safety and effect of pirfenidone on disease progression in such...
We conducted a single-centre, randomised, double-blinded, placebo-controlled trial in adults with FHP and disease progression. Patients were assigned in a 2:1 ratio to receive either oral pirfenidone ...
After randomising 40 patients, enrolment was interrupted by the COVID-19 pandemic. There was no significant between-group difference in FVC% at week 52 (mean difference -0.76%, 95% CI -6.34 to 4.82). ...
The trial was underpowered to detect a difference in the primary end point. Pirfenidone was found to be safe and improved PFS in patients with FHP....
NCT02958917....
Pain after soft tissue injuries in and around the ankle is a troublesome process in terms of patient comfort and mobilization. The aim of this study was to compare the analgesic efficacy of intravenou...
We conducted a prospective, double-blind, randomized controlled study in a tertiary hospital. The patients were divided into two groups as those administered IV 400 mg ibuprofen and IV 20 mg tenoxicam...
One hundred and twenty-four patients were included in the study. There were 62 patients in the tenoxicam group and 62 patients in the ibuprofen group. When VAS scores were compared, it was found that ...
We hypothesize that synbiotic supplementation could modulate the intestinal microbiota and subsequently, improve the condition of hypothyroid patients....
Fifty-six adult hypothyroid patients were recruited to this double-blind, placebo-controlled, randomized clinical trial. The intervention was 10 weeks of synbiotic (500 mg of 109 CFU/g probiotics plus...
Analysis on 51 patients who completed the trial showed that TSH and depression (p> 0.05) did not change significantly, while serum FT4 significantly increased in both groups (p = 0.03 and p = 0.02 in ...
Ten-week supplementation with synbiotic had no favorable effect on depression and TSH, but it improved blood pressure and quality of life in patients with hypothyroidism. More trials are needed to sup...
IRCT20210926052583N1, Iranian Registry of Clinical Trials (IRCT), registered October 1st, 2021....